BindingDB

The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.2M data for 1.4M Compounds and 11.4K Targets. Of those, 1.6M data for 756K Compounds and 4.8K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

Donate Now

To help with training and testing AI and other models, BindingDB downloads and search results now provide the publication date and BindingDB curation date of each measurement.

Advanced Search

27 articles for H Monenschein

The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
Synthesis and preliminary biological evaluation of potent and selective 2-(3-alkoxy-1-azetidinyl) quinolines as novel PDE10A inhibitors with improved solubility.EBI
TBA
Optimization of potency and pharmacokinetic properties of tetrahydroisoquinoline transient receptor potential melastatin 8 (TRPM8) antagonists.EBI
Amgen
Hydroxyethylamine-based inhibitors of BACE1: P1-P3 macrocyclization can improve potency, selectivity, and cell activity.EBI
Amgen
Design and synthesis of potent, orally efficacious hydroxyethylamine derivedß-site amyloid precursor protein cleaving enzyme (BACE1) inhibitors.EBI
Amgen
Design and preparation of a potent series of hydroxyethylamine containingß-secretase inhibitors that demonstrate robust reduction of centralß-amyloid.EBI
Amgen
A Potent and Orally Efficacious, Hydroxyethylamine-Based Inhibitor of ß-Secretase.EBI
TBA
Structure guided P1' modifications of HEA derivedß-secretase inhibitors for the treatment of Alzheimer's disease.EBI
Envoy Therapeutics
2-Aminothiadiazole inhibitors of AKT1 as potential cancer therapeutics.EBI
Amgen
First-Time Disclosure of CVN424, a Potent and Selective GPR6 Inverse Agonist for the Treatment of Parkinson's Disease: Discovery, Pharmacological Validation, and Identification of a Clinical Candidate.EBI
Takeda California
Discovery of TAK-041: a Potent and Selective GPR139 Agonist Explored for the Treatment of Negative Symptoms Associated with Schizophrenia.EBI
Takeda California
Discovery of TRPM8 Antagonist ( S)-6-(((3-Fluoro-4-(trifluoromethoxy)phenyl)(3-fluoropyridin-2-yl)methyl)carbamoyl)nicotinic Acid (AMG 333), a Clinical Candidate for the Treatment of Migraine.EBI
TBA
Inhibitors of integrated stress response pathwayBDB
Praxis Biotech
JAK inhibitors containing a 4-membered heterocyclic amideBDB
Theravance Biopharma R&D Ip
Dihydropyrrolopyridine inhibitors of ROR-gammaBDB
Vitae Pharmaceuticals
4-alkoxy/aralkoxy-5-substituted-pyrrolopyrimidine compounds as TAK1 inhibitors in disease treatmentBDB
Confluence Life Sciences
Inhibitory effect of novel pyrazole carboxamide derivatives on human carbonic anhydrase enzyme.BDB
Dumlupinar University
Nicotinic receptor compoundsBDB
Research Triangle Institute
1,2,6-substituted benzimidazoles as flap modulatorsBDB
Janssen Pharmaceutica
Substituted 3-heteroaroylamino-propionic acid derivatives and their use as pharmaceuticalsBDB
Sanofi
FAK inhibitorsBDB
Cancer Therapeutics Crc
Design and synthesis of newer potential 4-(N-acetylamino)phenol derived piperazine derivatives as potential cognition enhancers.BDB
Panjab University
Amino tetrahydro-pyridopyrimidine PDE10 inhibitorsBDB
Merck Sharp & Dohme
17Beta-hydroxysteroid dehydrogenase type 1 inhibitors for the treatment of hormone-related diseasesBDB
Universitaet Des Saarlandes
Desensitization of the human motilin receptor by motilides.BDB
Katholieke Universiteit Leuven
Novel small-molecule inhibitors of anthrax lethal factor identified by high-throughput screening.BDB
Montana State University